AlphAIalphai — Financial news for AI agents
Zacks CommentaryNOV 183 min read$TVRD

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 18, 2025, 2:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 19, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now — source image
Source · www.zacks.com
Decision brief

The 30-second read

$TVRDBullishMed
01

Why it matters

The combination of technical support and positive earnings revisions suggests a potential short-term rebound, though risks remain if broader market conditions deteriorate.

02

Market read

The news is moderately relevant for traders interested in short-term technical rebounds in TVRD.

03

What to watch

Potential negative news catalysts or sector-wide downturns could negate technical signals and earnings optimism.

Timing: Short-term (1-3 weeks)

Background

Tvardi (TVRD) has experienced recent declines, but technical analysis indicates a possible bottoming pattern, supported by improving earnings estimates.

Company-level read

Ticker impact

$TVRDBullishMedium confidence
Context

The news article discusses Tvardi (TVRD), highlighting technical chart patterns and earnings estimate revisions that could signal a potential trend reversal.

Expected impact

Moderate upward movement in the near term, with potential for a short-term rally if support holds.

Evidence & confidence

Technical support patterns and positive earnings revisions suggest a potential reversal, but lack of current price data and broader market context introduce uncertainty.

Market effects

Sector

Potential positive sentiment for biotech or pharmaceutical sectors if TVRD is within these industries.

Regional

Limited regional impact; primarily relevant to investors focused on the company's sector.

Global

Minimal global market impact due to company-specific news.

Counterpoint

What could challenge this read

The stock may continue to decline if support levels fail or broader market conditions turn bearish.

Key entities

  • Company
    Tvardi

    Biotech or pharmaceutical company under discussion.

Read at source← All news

Related articles

JUL 7
$TVRDMedAI 8/10

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

investorideas.com4 min
JUL 7
$TVRDMed

Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study

Tvardi Therapeutics (TVRD) reported Phase 1 results for TTI-109, a phosphate prodrug of TTI-101. The drug converted rapidly and showed plasma exposure similar to TTI-101 at equivalent doses, with repeat dosing maintaining levels above the STAT3 inhibitory threshold for 21 days. Exploratory data showed up to 60% reductions in STAT3-driven immune cells and shorter diarrhea duration vs TTI-101. Phase 2 is planned pending funding.

rttnews.com3 min
JUL 7
$TVRDMedAI 8/10

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.

benzinga.com4 min
JUL 7
$TVRDMedAI 8/10

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug of TTI-101. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional PK with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60%. It plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and funding; webcast July 7, 8:30am ET.

manilatimes.net4 min
JUN 30
$UPCMed

Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?

Biotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.

rttnews.com6 min